Trial Profile
Infliximab as First Line Therapy in Patients With Early Active Axial Spondyloarthritis Trial.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs Infliximab (Primary) ; Naproxen
- Indications Axial spondyloarthritis; Spondylarthritis
- Focus Therapeutic Use
- Acronyms INFAST
- Sponsors Merck Sharp & Dohme Corp.
- 13 Jul 2016 Results of a post-hoc analysis published in the Rheumatology
- 25 Mar 2016 Results published in the Arthritis and Rheumatology
- 13 Jun 2015 Results (part I)presented at the 16th Annual Congress of the European League Against Rheumatism.